Patents Assigned to CSL Limited
  • METHOD OF TREATING OR PREVENTING STROKE
    Publication number: 20190315849
    Abstract: A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.
    Type: Application
    Filed: May 14, 2019
    Publication date: October 17, 2019
    Applicants: CSL Limited, B-Creative Sweden AB
    Inventors: Ulf ERIKSSON, Ingrid NILSSON, Daniel LAWRENCE, Enming Joe SU
  • Process for preparing Apolipoprotein A-I (Apo A-I)
    Patent number: 10421799
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 24, 2019
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Method of treating diabetic nephropathy in a subject suffering from type 2 diabetes by administering an antibody which inhibits VEGF-B signaling
    Patent number: 10407498
    Abstract: The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 10, 2019
    Assignees: CSL LIMITED, B-CREATIVE SWEDEN AB
    Inventors: Ulf Eriksson, Annelie Falkevall, Annika Mehlem
  • Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent
    Patent number: 10336821
    Abstract: A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: July 2, 2019
    Assignees: CSL Limited, B-Creative Sweden AB
    Inventors: Ulf Eriksson, Ingrid Nilsson, Daniel Lawrence, Enming Joe Su
  • Reconstituted high density lipoprotein formulation and production method thereof
    Patent number: 10335457
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 2, 2019
    Assignee: CSL LIMITED
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • CONTAMINANT REMOVAL METHOD
    Publication number: 20190119354
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Application
    Filed: July 20, 2018
    Publication date: April 25, 2019
    Applicant: CSL Limited
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Method to concentrate von willebrand factor or complexes thereof
    Patent number: 10246485
    Abstract: The present invention relates to a method for concentrating von Willebrand Factor (VWF) from an aqueous solution comprising precipitating the VWF by providing calcium ions and phosphate ions and the subsequent resolubilization of the VWF by means of an aqueous solution comprising a calcium complexing compound.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: April 2, 2019
    Assignee: CSL LIMITED
    Inventors: Holger Lind, Sonja Beckmann-Scheld, Katharina Propp
  • Factor VIII formulation
    Patent number: 10238718
    Abstract: The invention relates to factor VIII compositions and their use.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: March 26, 2019
    Assignee: CSL LIMITED
    Inventors: Uwe Liebing, Hubert Metzner, Christina Bodenbender
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20190055313
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 21, 2019
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • RECONSTITUTED HDL FORMULATION
    Publication number: 20190015476
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Application
    Filed: February 12, 2018
    Publication date: January 17, 2019
    Applicant: CSL Limited
    Inventors: Yvonne Vucica, Gary Lee Warren
  • High affinity antibody antagonists of interleukin-13 receptor alpha 1
    Patent number: 10106617
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 23, 2018
    Assignee: CSL LIMITED
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • PROCESS FOR PREPARING APOLIPOPROTEIN A-I (APO A-I)
    Publication number: 20180298080
    Abstract: The present invention relates to processes of obtaining Apo A-I from an Apo A-I containing protein fraction (A), comprising suspending the Apo A-I containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-I proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-I precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-I, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Application
    Filed: January 12, 2018
    Publication date: October 18, 2018
    Applicant: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Contaminant removal method
    Patent number: 10087235
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nrn to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-f preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: October 2, 2018
    Assignee: CSL LIMITED
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • METHOD OF TREATING OR PREVENTING STROKE
    Publication number: 20180237513
    Abstract: A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling
    Type: Application
    Filed: November 17, 2015
    Publication date: August 23, 2018
    Applicants: CSL Limited, B-Creative Sweden AB
    Inventors: Ulf ERIKSSON, Ingrid NILSSON, Daniel LAWRENCE, Enming Joe SU
  • Humanized anti-interleukin 3 receptor alpha chain antibodies
    Patent number: 10047161
    Abstract: The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 14, 2018
    Assignee: CSL Limited
    Inventor: Con Panousis
  • Method for improving the stability of purified factor VIII after reconstitution
    Patent number: 9956269
    Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: May 1, 2018
    Assignee: CSL Limited
    Inventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
  • METHOD OF TREATING NEPHROPATHY
    Publication number: 20180086824
    Abstract: The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.
    Type: Application
    Filed: September 28, 2017
    Publication date: March 29, 2018
    Applicants: CSL LIMITED, B-CREATIVE SWEDEN AB
    Inventors: Ulf ERIKSSON, Annelie FALKEVALL, Annika MEHLEM
  • Reconstituted HDL formulation
    Patent number: 9925236
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 27, 2018
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • METHOD OF INHIBITION OF LEUKEMIC STEM CELLS
    Publication number: 20180079818
    Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.
    Type: Application
    Filed: May 5, 2017
    Publication date: March 22, 2018
    Applicants: CSL Limited, University Health Network
    Inventors: John Edgar Dick, Liqing JIN, Gino Luigi VAIRO, David Paul GEARING, Samantha Jane BUSFIELD
  • Process for preparing apolipoprotein A-I (Apo A-I)
    Patent number: 9890203
    Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 13, 2018
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren